OncRef

Clinical Trial: NCT03811002

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 3

Lead Sponsor:National Cancer Institute (NCI)
Information Provided By:National Cancer Institute (NCI)
Last Update Posted:2026-08-27

Study Overview

Brief Summary

This phase III trial studies how well chemotherapy and radiation therapy (chemoradiation) with or without atezolizumab works in treating patients with limited stage small cell lung cancer. Drugs used in chemotherapy, such as etoposide, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving chemoradiation with or without atezolizumab may work better in treating patients with limited stage small cell lung cancer.

Official Title

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab

Conditions

Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8

Intervention / Treatment

  • Radiation: 3-Dimensional Conformal Radiation Therapy
  • Drug: Atezolizumab
  • Procedure: Biospecimen Collection
  • Drug: Carboplatin
  • Drug: Cisplatin
  • Drug: Etoposide
  • Radiation: Intensity-Modulated Radiation Therapy
  • Other: Quality-of-Life Assessment
  • Other: Questionnaire Administration

Other Study ID Numbers

  • NCI-2019-00178
  • NCI-2019-00178
  • NRG-LU005
  • NRG-LU005
  • U10CA180868

Start Date (Actual)

2019-07-26

Primary Completion Date (Actual)

2024-04-21

Study Completion Date (Estimated)

2029-02-21

Enrollment (Actual)

544

Study Type

Interventional

Phase

Phase 3